Helical Tomotherapy in Multiple Myeloma
ConditionMultiple Myeloma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFuling Zhou
About this trial
To explore the safety and efficacy of systemic radiotherapy (TBI) combined with melphalan (Mel) for pretreatment of autologous hematopoietic stem cells in multiple myeloma.
Eligibility criteria
Qualifiers
Multiple myeloma patients receiving induction therapy and stem cell mobilization preparation for autologous transplantation;
Should agree to comply with all contraceptive requirements; 3, ECOG≤2;
Disqualifiers
According to the investigator's judgment, patients who cannot tolerate melphalan and radiotherapy;
Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV), or seropositive for human immunodeficiency virus (HIV);
patients with uncontrolled or severe cardiovascular disease
According to the protocol or the investigator's judgment, the patient has a serious physical or mental illness
Trial design
Treatments tested in this trial
- Total Marrow irradiation，TMI
- Autologous hematopoietic stem cell transplantation
Treatment groups
58 Participants
are divided into 2 treatment groupsSponsors and collaborators
Fuling Zhou
Lead sponsor
Zhongnan Hospital
Sponsor institution
Source ClinicalTrials.gov